Thomas Franklin Westbrook
Affiliations: | 2008- | Biochemistry and Molecular Biology | Baylor College of Medicine, Houston, TX |
Area:
cancer research, genetics, technology, therapeuticsWebsite:
https://profiles.viictr.org/display/BCM/thomas-westbrookGoogle:
"Thomas Franklin Westbrook"Bio:
https://www.bcm.edu/people/view/trey-westbrook-ph-d/baylor-college-of-medicine-faculty-graduate-faculty-r-z-biochemistry-and-molecular-biology/b26b8e5c-ffed-11e2-be68-080027880ca6/55b7f1cd-55c8-463b-bd07-22310a591328
https://www.bcm.edu/research/labs/thomas-westbrook
https://scholar.google.com/citations?user=IBOcY8nCwAYC&hl=en
Parents
Sign in to add mentorDennis J. McCance | grad student | 1998-2002 | Rochester (Microtree) | |
(Mislocalization of Cip /Kip CDK inhibitors and dysregulation of cellular proliferation by the HPV16 E7 oncoprotein.) | ||||
Stephen J. Elledge | post-doc | 2003-2007 | Harvard Medical School (Chemistry Tree) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Meena JK, Wang JH, Neill NJ, et al. (2024) MYC Induces Oncogenic Stress through RNA Decay and Ribonucleotide Catabolism in Breast Cancer. Cancer Discovery. OF1-OF18 |
Cai WL, Chen JF, Chen H, et al. (2022) Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation. Elife. 11 |
Gao Y, Kabotyanski EB, Shepherd JH, et al. (2021) Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Cancer Research Communications. 1: 178-193 |
Einstein JM, Perelis M, Chaim IA, et al. (2021) Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Molecular Cell |
Krug K, Jaehnig EJ, Satpathy S, et al. (2020) Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell |
Arnal-Estapé A, Cai WL, Albert AE, et al. (2020) Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6. Oncogene |
Gao Y, Kabotyanski E, Acosta D, et al. (2020) Abstract P4-08-01: Tumor suppressor PLK2 may serve as a biomarker in triple negative breast cancer for combinational therapy of PLK1 inhibitors with the standard-of-care chemotherapy Cancer Research. 80 |
Hirukawa A, Singh S, Wang J, et al. (2019) Reduction of Global H3K27me Enhances HER2/ErbB2 Targeted Therapy. Cell Reports. 29: 249-257.e8 |
Kim IS, Gao Y, Welte T, et al. (2019) Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nature Cell Biology |
Mowery CT, Reyes JM, Cabal-Hierro L, et al. (2018) Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression. Cell Reports. 25: 1898-1911.e5 |